[1]梁 娜,张泽天,孙晓冉,等.低密度脂蛋白相关受体蛋白6基因多态性与非酒精性脂肪性肝病发病关系研究[J].陕西医学杂志,2023,52(9):1241-1244.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.030]
　LIANG Na,ZHANG Zetian,SUN Xiaoran,et al.Relationship between low-density lipoprotein receptor-related protein 6 gene polymorphism and occurrence of nonalcoholic fatty liver disease[J].,2023,52(9):1241-1244.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.030]
点击复制

低密度脂蛋白相关受体蛋白6基因多态性与非酒精性脂肪性肝病发病关系研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年9期
页码:
1241-1244
栏目:
临床检验
出版日期:
2023-09-05

文章信息/Info

Title:
Relationship between low-density lipoprotein receptor-related protein 6 gene polymorphism and occurrence of nonalcoholic fatty liver disease
作者:
梁 娜; 张泽天; 孙晓冉; 李 多
(河北北方学院附属第一医院消化内科,河北 张家口 075000)
Author(s):
LIANG Na; ZHANG Zetian; SUN Xiaoran; LI Duo
(Department of Gastroenterology,the First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,China)
关键词:
非酒精性脂肪性肝病;  低密度脂蛋白相关受体蛋白6;  基因多态性;  rs2302685位点;  基因型分布
Keywords:
Nonalcoholic fatty liver disease;  Low-density lipoprotein receptor-related protein 6;  Gene polymorphism;  rs2302685 locus;  Genotype distribution
分类号:
R 575.5
DOI:
DOI:10.3969/j.issn.1000-7377.2023.09.030
文献标志码:
A
摘要:
目的:探究低密度脂蛋白相关受体蛋白6(LRP6)基因多态性与非酒精性脂肪性肝病(NAFLD)发病的关系。方法:选取NAFLD患者(NAFLD组)144例和体检健康者(对照组)135例为研究对象。检测两组血清丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、载脂蛋白B(ApoB)以及ApoA1水平; 提取两组血清中基因组DNA,采用PCR法扩增LRP6基因rs2302685片段并测序; 比较两组一般资料和生化指标; 观察两组LRP6基因rs2302685位点基因型分布并进行Hardy-Weinberg(H-W)遗传平衡检验; 比较不同LRP6基因型NAFLD患者生化指标; 采用Logistic回归分析LRP6基因型对NAFLD发生的影响。结果:与对照组比较,NAFLD组体重指数(BMI)及ALT、TG、LDL-C、ApoB水平升高(均P<0.05)。对照组和NAFLD组LRP6基因在rs2302685位点上均检出TT型、TC型、CC型3种基因型,其中对照组TT基因型最多(57.78%),NAFLD组CC基因型最多(56.94%),对照组与NAFLD组基因型比较差异有统计学意义(P<0.05)。经吻合度检验,对照组和NAFLD组基因多态性分布符合H-W平衡法则(均P>0.05)。TT型、TC型、CC型NAFLD患者BMI、ALT、TG、LDL-C、ApoB水平依次升高(均P<0.05)。CC基因型是影响NAFLD发生的独立危险因素(P<0.05)。结论:LRP6基因多态性与NAFLD有关,其中CC基因型是影响NAFLD发生的独立危险因素。
Abstract:
Objective:To explore the relationship between low-density lipoprotein receptor-related protein 6(LRP6)gene polymorphism and occurrence of nonalcoholic fatty liver disease(NAFLD).Methods:A total of 144 patients with NAFLD(NAFLD group)and 135 healthy subjects(control group)were selected.Automatic biochemical analyzer was used to detect the levels of ALT,AST,TG,TC,LDL-C,HDL-C,apolipoprotein B(ApoB)and ApoA1.Genomic DNA was extracted from serum,the rs2302685 fragment of LRP6 gene was amplified by PCR and sequenced.General data,biochemical indexes,genotype distribution of rs2302685 polymorphism of LRP6 gene and Hardy-Weinberg(H-W)genetic balance test were performed.Biochemical indexes of NAFLD patients with different LRP6 genotypes were compared.Logistic regression was used to analyze the influence of LRP6 genotype on the occurrence of NAFLD.Results:Compared with control group,BMI,ALT,TG,LDL-C and ApoB levels were increased in the NAFLD group(all P<0.05).Three genotypes of TT type,TC type and CC type of the LRP6 gene were detected at the rs2302685 locus of the two groups,and among them,the control group had the most TT genotype(57.78%),and the NAFLD group had the most CC genotype(56.94%),there was statistically significant difference in genotype between the control group and the NAFLD group(P<0.05).After the degree of coincidence test,the distribution of gene polymorphisms in the control group and NAFLD group conformed to the H-W equilibrium law(all P>0.05).The levels of BMI,ALT,TG,LDL-C and ApoB in patients with TT type,TC type and CC type NAFLD were increased successively(all P<0.05).CC genotype was an independent risk factor affecting the occurrence of NAFLD(P<0.05).Conclusion:LRP6 gene polymorphism is related to NAFLD,and CC genotype is an independent risk factor affecting occurrence of NAFLD.

参考文献/References:

[1] 林先佳,王小锋,张媛媛,等.基于网络药理学和分子对接探讨肝脂平治疗非酒精性脂肪性肝病作用机制[J].陕西中医,2023,44(4):524-529.
[2] Xie J,Huang H,Liu Z,et al.The associations between modifiable risk factors and nonalcoholic fatty liver disease:A comprehensive mendelian randomization study[J].Hepatology,2023,77(3):949-964.
[3] 安 欣,刘鲁豫,王成凯.2型糖尿病患者尿微量白蛋白肌酐比值与非酒精性脂肪性肝病相关性分析[J].陕西医学杂志,2021,50(11):1416-1419.
[4] Hou T,Tian Y,Cao Z,et al.Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation[J].Mol Cell,2022,82(21):4099-4115.
[5] Wu Y,Zhou L,Liu H,et al.LRP6 downregulation promotes cardiomyocyte proliferation and heart regeneration[J].Cell Res,2021,31(4):450-462.
[6] 王秀梅,李昌平.microRNA-21在非酒精性脂肪肝病中的分子机制[J].分子影像学杂志,2019,42(1):87-90.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].中华肝脏病杂志,2018,26(3):195-203.
[8] Lee CH,Lui DT,Lam KS.Non-alcoholic fatty liver disease and type 2 diabetes:An update[J].J Diabetes Investig,2022,13(6):930-940.
[9] 刘玲娇,余湘尤,虢小丽.西安市职业人群非酒精性脂肪性肝病患病率及其危险因素调查研究[J].陕西医学杂志,2021,50(1):107-110.
[10] Lazarus JV,Mark HE,Anstee QM,et al.Advancing the global public health agenda for NAFLD:A consensus statement[J].Nat Rev Gastroenterol Hepatol,2022,19(1):60-78.
[11] 唐颖慧,叶苗青,何瑾瑜,等.化脂复肝颗粒通过抑制TLR4/NF-κB/NLRP3减轻Kupffer细胞炎症改善非酒精性脂肪性肝病机制研究[J].陕西中医,2022,43(10):1359-1363,1368.
[12] Tilg H,Adolph TE,Dudek M,et al.Non-alcoholic fatty liver disease:The interplay between metabolism,microbes and immunity[J].Nat Metab,2021,3(12):1596-1607.
[13] Khneizer G,Rizvi S,Gawrieh S.Non-alcoholic fatty liver disease and diabetes mellitus[J].Adv Exp Med Biol,2021,1307(1):417-440.
[14] Juanola O,Martínez-López S,Francés R,et al.Non-alcoholic fatty liver disease:Metabolic,genetic,epigenetic and environmental risk factors[J].Int J Environ Res Public Health,2021,18(10):5227.
[15] Cataldo I,Sarcognato S,Sacchi D,et al.Pathology of non-alcoholic fatty liver disease[J].Pathologica,2021,113(3):194-202.
[16] Tang S,Zhang J,Mei TT,et al.Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children:A meta-analysis[J].BMC Med Genet,2020,21(1):163.
[17] Dai G,Liu P,Li X,et al.Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease(NAFLD)susceptibility and severity:A meta-analysis[J].Medicine(Baltimore),2019,98(7):e14324.
[18] 姜 华,高建鹏,胡 阳,等.肝性脂肪酸结合蛋白基因单核苷酸多态性表达与NAFLD的相关性[J].实用医学杂志,2020,36(1):84-88.
[19] Liu Z,Li C,Liu M,et al.The low-density lipoprotein receptor-related protein 6 pathway in the treatment of intestinal barrier dysfunction induced by hypoxia and intestinal microbiota through the Wnt/β-catenin pathway[J].Int J Biol Sci,2022,18(11):4469-4481.
[20] Chen LJ,Lin XX,Guo J,et al.Lrp6 genotype affects individual susceptibility to nonalcoholic fatty liver disease and silibinin therapeutic response via Wnt/β-catenin-Cyp2e1 signaling[J].Int J Biol Sci,2021,17(14):3936-3953.
[21] Diaz A,Martin-Jimenez C,Woo Y,et al.Urokinase-type plasminogen activator triggers wingless/int1-independent phosphorylation of the low-density lipoprotein receptor-related protein-6 in cerebral cortical neurons[J].J Alzheimers Dis,2022,89(3):877-891.
[22] Chow HM,Sun JK,Hart RP,et al.Low-density lipoprotein receptor-related protein 6 cell surface availability regulates fuel metabolism in astrocytes[J].Adv Sci(Weinh),2021,8(16):e2004993.
[23] 付世青,谭洁琼,王 芳.低密度脂蛋白受体相关蛋白6的功能及其在疾病研究中的进展[J].中国动脉硬化杂志,2021,29(12):1099-1104.
[24] Mineo C.Lipoprotein receptor signalling in atherosclerosis[J].Cardiovasc Res,2020,116(7):1254-1274.

相似文献/References:

[1]刘 颖,李远辙,周声毅,等.脉冲电磁场调控SREBP1c及氧化应激改善db/db小鼠肝脂肪变性研究*[J].陕西医学杂志,2019,(9):1107.
　LIU Ying,LI Yuanzhe,ZHOU Shengyi,et al.Pulsed electromagnetic fields improves hepatic steatosis 〖JZ〗in db/db mice by SREBP1c and oxidative stress[J].,2019,(9):1107.
[2]刘玲娇,余湘尤,虢小丽.西安市职业人群非酒精性脂肪性肝病患病率及其危险因素调查研究[J].陕西医学杂志,2021,50(1):107.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.029]
　LIU Lingjiao,YU Xiangyou,GUO Xiaoli.Prevalence and risk factors of nonalcoholic fatty liver disease among occupational population in Xi'an[J].,2021,50(9):107.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.029]
[3]李 婧,李小凤,闫 妮,等.胰岛素抵抗代谢评分在中老年人群非酒精性脂肪性肝病筛查中的价值研究[J].陕西医学杂志,2023,52(6):688.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.011]
　LI Jing,LI Xiaofeng,YAN Ni,et al.Value of metabolic score for insulin resistance in screening non-alcoholic fatty liver disease in middle-aged and elderly people[J].,2023,52(9):688.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.011]
[4]赵梦溪,罗 斌,吕建瑞,等.隐丹参酮治疗小鼠非酒精性脂肪性肝病效果及机制研究[J].陕西医学杂志,2023,52(9):1135.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.005]
　ZHAO Mengxi,LUO Bin,LYU Jianrui,et al.Effect and mechanism of cryptotanshinone on nonalcoholic fatty liver disease in mice[J].,2023,52(9):1135.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.005]

备注/Memo

备注/Memo:
基金项目:河北省医学科学研究课题(20210385)
更新日期/Last Update: 2023-09-04